U.S. markets open in 3 hours 7 minutes
  • S&P Futures

    4,362.00
    -59.75 (-1.35%)
     
  • Dow Futures

    33,907.00
    -555.00 (-1.61%)
     
  • Nasdaq Futures

    15,161.75
    -164.25 (-1.07%)
     
  • Russell 2000 Futures

    2,187.00
    -41.30 (-1.85%)
     
  • Crude Oil

    70.38
    -1.59 (-2.21%)
     
  • Gold

    1,760.20
    +8.80 (+0.50%)
     
  • Silver

    22.47
    +0.13 (+0.57%)
     
  • EUR/USD

    1.1722
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    1.3700
    0.0000 (0.00%)
     
  • Vix

    25.14
    +6.45 (+34.51%)
     
  • GBP/USD

    1.3694
    -0.0044 (-0.32%)
     
  • USD/JPY

    109.6430
    -0.2520 (-0.23%)
     
  • BTC-USD

    45,086.35
    -2,964.05 (-6.17%)
     
  • CMC Crypto 200

    1,126.35
    -99.18 (-8.09%)
     
  • FTSE 100

    6,853.87
    -109.77 (-1.58%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Here is Why Growth Investors Should Buy Alexion (ALXN) Now

·3 min read

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.

By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.

However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.

Alexion Pharmaceuticals (ALXN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.

Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.

While there are numerous reasons why the stock of this drugmaker is a great growth pick right now, we have highlighted three of the most important factors below:

Earnings Growth

Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Alexion is 31.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 11.1% this year, crushing the industry average, which calls for EPS growth of 8.7%.

Cash Flow Growth

While cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds.

Right now, year-over-year cash flow growth for Alexion is 93.1%, which is higher than many of its peers. In fact, the rate compares to the industry average of 16.4%.

While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 34.2% over the past 3-5 years versus the industry average of 7.1%.

Promising Earnings Estimate Revisions

Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The current-year earnings estimates for Alexion have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.1% over the past month.

Bottom Line

Alexion has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

This combination indicates that Alexion is a potential outperformer and a solid choice for growth investors.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research